文献速递血栓与止血

血友病治疗创新:50年进展与未来展望

Hemophilia treatment innovation: 50 years of progress and more to come.
PubMed 文献 · J Thromb Haemost · 2023-01-01

本文回顾了自20世纪70年代以来血友病治疗的显著进展,重点梳理了近10年的突破。为应对预防治疗依从性不足的问题,延长半衰期的凝血因子VIII和IX产品以及首个非因子皮下药物艾美珠单抗相继问世;基因治疗产品也已于2022年获批用于成人血友病A和B,实现治愈的可能。文章进一步展望未来进展及个体化治疗选择。

要点

  • 延长半衰期凝血因子VIII和IX产品及艾美珠单抗改善了预防治疗依从性与有效性。
  • 艾美珠单抗是首个用于血友病A(伴或不伴抑制物)的非因子皮下治疗药物。
  • 基因治疗产品于2022年获批用于成人血友病A和B,向治愈迈出一步。

核心结论

  • 血友病治疗在过去50年取得显著进展,近10年尤为突出,未来仍有进一步进展空间。
  • 延长半衰期因子产品、艾美珠单抗和基因治疗等新选择使个体化治疗决策成为可能。

研究设计与样本

  • 综述性文章,回顾自20世纪70年代以来的血友病治疗进展。

主要发现

  • 延长血浆半衰期的凝血因子VIII和IX产品以及艾美珠单抗被开发用于解决预防治疗依从性与有效性问题。
  • 艾美珠单抗是首个用于血友病A(伴或不伴抑制物)患者的非因子皮下药物。
  • 基因治疗的首批产品于2022年获批用于成人血友病A和B。

临床怎么用

  • 患者及其照护提供者可在广泛治疗选择中进行个体化决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the goal of emphasizing the striking advances that materialized in hemophilia care particularly in the last 10 years, the progress of knowledge that started from the 1970s will first be sketched as background. Subsequently, the unmet needs pertaining to therapeutic adherence and thus to prophylaxis effectiveness led to the availability of factor VIII and IX products with an extended plasma half-life as well as to emicizumab, the first nonfactor medicine for subcutaneous administration in patients with hemophilia A with or without inhibitor. The issue of a still lacking cure for the disease is approached by means of gene therapy, the first products of which were approved in 2022 for adults with both hemophilia types. Finally, views will be offered on further progress that is expected in the next few years and how patients and their care providers may make personalized choices among the wide array of therapeutic options.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Mannucci PM. Hemophilia treatment innovation: 50 years of progress and more to come. J Thromb Haemost. 2023. PMID: 36858789. doi:10.1016/j.jtha.2022.12.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。